Articles from Novastra Therapeutics Inc.

CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Novastra Therapeutics, a clinical-stage biotechnology company developing a novel category of cancer immune therapy, today announced the creation of a Scientific Advisory Board (SAB) and the appointment of senior advisors and a Head of Clinical Development. The group of recognized leaders in immuno-oncology, medical oncology, clinical development, and regulatory affairs will guide and support the advancement of programs based on the company’s proprietary OmniAntigen™ Platform (OAP) through scientific validation and further development.

CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Novastra Therapeutics, a clinical-stage biotechnology company developing a novel category of cancer immune therapy, today announced that first-in-human data from an ongoing investigator-initiated Phase 1 study of OAP-101 in anti-PD-1-refractory advanced melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

CAMBRIDGE, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Novastra Therapeutics, a clinical-stage biotechnology company developing a novel category of cancer immune therapy, reported encouraging initial data from an ongoing investigator-initiated Phase 1 study representing the first clinical evidence for its systematic immune reprogramming therapy (XIRT™) based on its proprietary OmniAntigen™ Platform (OAP). The data were presented on Saturday, October 24, at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Novastra Therapeutics, a clinical-stage biotechnology company developing a novel category of cancer immune therapy, today announced that initial clinical data from an ongoing investigator-initiated Phase 1 study of its candidate OAP-101 in anti-PD-1-refractory advanced melanoma will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Novastra Therapeutics, a clinical-stage biotech company developing a novel category of cancer immune therapy, today announced the appointment of Jarett Poll as fractional Chief Financial Officer. Jarett brings senior leadership experience from Alfasigma, where he led U.S. Business Development, and from prior roles in healthcare investment banking and private capital investing.